Pyxis Oncology (PYXS) Stock Forecast & Price Target

$2.13 -1.69 (-44.24%)

(As of 12:20 PM ET)

Pyxis Oncology - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Pyxis Oncology in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for PYXS.

Consensus Price Target

$10.00
369.48% Upside

According to the 9 analysts' twelve-month price targets for Pyxis Oncology, the average price target is $10.00. The highest price target for PYXS is $13.00, while the lowest price target for PYXS is $7.00. The average price target represents a forecasted upside of 369.48% from the current price of $2.13.

Get the Latest News and Ratings for PYXS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pyxis Oncology and its competitors.

PYXS Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.00	$9.00	$9.00	$10.50
Forecasted Upside	369.48% Upside	156.41% Upside	142.59% Upside	650.00% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Buy

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

PYXS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PYXS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pyxis Oncology Stock vs. The Competition

Type	Pyxis Oncology	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	150.56% Upside	26,931.55% Upside	9.81% Upside
News Sentiment Rating	Neutral News See Recent PYXS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/21/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$7.00 ➝ $10.00	+395.05%
11/21/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00	+83.25%
11/21/2024	William Blair 2 of 5 stars		Downgrade	Outperform ➝ Market Perform
11/8/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00	+229.95%
8/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$10.00	+219.49%
5/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$10.00	+132.02%
2/9/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$8.00	+115.63%
1/23/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. La. Rosa Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/23/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$12.00	+370.59%
4/26/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/23/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$14.00	+536.36%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:47 PM ET.

PYXS Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Pyxis Oncology is $10.00, with a high forecast of $13.00 and a low forecast of $7.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PYXS shares.
: According to analysts, Pyxis Oncology's stock has a predicted upside of 369.48% based on their 12-month stock forecasts.
: Over the previous 90 days, Pyxis Oncology's stock had 1 downgrade by analysts.
: Pyxis Oncology has been rated by research analysts at HC Wainwright, Royal Bank of Canada, Stephens, and William Blair in the past 90 days.
: Analysts like Pyxis Oncology more than other "medical" companies. The consensus rating score for Pyxis Oncology is 2.89 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PYXS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

This page (NASDAQ:PYXS) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Stock Forecast & Price Target